Moreover, long-term ibrutinib therapy is likely to reverse the pseudo-exhaustion of T cells and promote the activity of effector T cells in CLL patients by inhibiting ITK activity and reducing the expression of inhibitory receptors (53, 83, 84). The gene discussed is ITK; the disease is B-cell chronic lymphocytic leukemia.